Spero Therapeutics (SPRO) Non Operating Income (2016 - 2026)
Spero Therapeutics posted quarterly Non Operating Income of -$1000.0 for Q1 2026, down 100.12% year-on-year from $865000.0 in Q1 2025, and up 99.95% on a QoQ basis from -$2.1 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Non Operating Income data on file, last reported at -$1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 100.12% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at -$859000.0 (up 45.29% YoY), and the FY2025 full-year result was $7000.0, down 88.33% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1000.0, up from -$2.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.2 million in Q2 2024 and bottomed at -$3.6 million in Q4 2024.
- The 5-year median for Non Operating Income is -$2000.0 (2023), against an average of -$170470.6.
- The widest annual swing landed in 2022, when Non Operating Income sank 8573.33%; it then soared 11722.22% in 2023.
- A 5-year view of Non Operating Income shows it stood at -$9000.0 in 2022, then jumped by 11722.22% to $1.0 million in 2023, then slumped by 444.93% to -$3.6 million in 2024, then jumped by 40.8% to -$2.1 million in 2025, then surged by 99.95% to -$1000.0 in 2026.
- The last three Non Operating Income figures came in at -$1000.0 (Q1 2026), -$2.1 million (Q4 2025), and $534000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 744,000.00 |
| Mar 31, 2025 | 865,000.00 |
| Dec 31, 2024 | -3.61 Mn |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | 976,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Dec 31, 2022 | -9,000.00 |
| Sep 30, 2022 | 159,000.00 |
| Jun 30, 2022 | -2.60 Mn |
| Mar 31, 2022 | -13,000.00 |
| Dec 31, 2021 | -78,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | -30,000.00 |
| Mar 31, 2021 | -118,000.00 |
| Dec 31, 2020 | 563,000.00 |
| Sep 30, 2020 | 84,000.00 |
| Jun 30, 2020 | 889,000.00 |
| Mar 31, 2020 | -437,000.00 |
| Dec 31, 2019 | 354,000.00 |
| Sep 30, 2019 | 268,000.00 |
| Jun 30, 2019 | 135,000.00 |
| Mar 31, 2019 | 385,000.00 |
| Dec 31, 2018 | -616,000.00 |
| Sep 30, 2018 | 472,000.00 |
| Jun 30, 2018 | 15,000.00 |
| Mar 31, 2018 | 172,000.00 |
| Dec 31, 2017 | 132,000.00 |
| Sep 30, 2017 | 122,000.00 |
| Jun 30, 2017 | 402,000.00 |
| Mar 31, 2017 | 1.19 Mn |
| Dec 31, 2016 | 613,000.00 |
| Sep 30, 2016 | -4,000.00 |